544445
Asston Pharmaceuticals Ltd
BSELast Traded Price
₹75.00
-1.50 (-1.96%)
Open
₹75.00
High
₹75.00
Low
₹75.00
Prev Close
₹76.50
Industry
Healthcare
Market Cap
63.84 Cr
Filing History
Recent corporate announcements and filings for 544445
Governance
Neutral
2026-07-09 16:50
- Asston Pharmaceuticals Limited to hold its 2nd Extraordinary General Meeting (EGM) on Friday, July 31, 2026, at 12:30 P.M. via Video Conferencing/Other Audio Visual Means.
- The EGM's agenda is to approve the issuance of up to 24,10,431 equity shares on a preferential basis at an issue price of ₹115 per share, aggregating up to ₹27,71,99,565/-.
- The cut-off date for determining e-voting eligibility is July 24, 2026.
Governance
Positive
2026-07-02 18:49
- Board of Directors approved the preferential issue of up to 24,10,431 Equity Shares at ₹115 per share, aggregating ₹27.72 Crores, to Non-Promoter category.
- An EGM will be convened on July 31, 2026, at 12:30 PM to obtain shareholder approval for the preferential issue.
Ownership
Positive
2026-07-02 18:43
- Board of Directors approved the preferential issue of up to 24,10,431 equity shares to persons belonging to the Non-Promoter category.
- The issue price is ₹115 per equity share, aggregating up to ₹27,71,99,565.
- An Extraordinary General Meeting (EGM) will be held on Friday, July 31, 2026, at 12:30 PM to seek shareholder approval for the proposed issue.
Governance
Positive
2026-07-02 18:37
- Board approved preferential issue of up to 24,10,431 equity shares at ₹115 per share, totaling ₹27.72 Crore, to non-promoters on a cash basis.
- An EGM is scheduled for July 31, 2026, at 12:30 PM to obtain shareholder approval for this preferential issue.
Ownership
Positive
2026-07-02 18:27
- Board approved preferential issue of up to 24,10,431 Equity Shares at ₹115 per share (totaling ₹27.72 Crores) to non-promoters for cash.
- An EGM is scheduled for July 31, 2026, at 12:30 PM to seek shareholder approval for the proposed issue.
Governance
Positive
2026-07-02 18:24
- Board of Directors approved the preferential issue of up to 24,10,431 Equity Shares at ₹115 per share, aggregating ₹27.72 Crores to Non-Promoters.
- An Extraordinary General Meeting (EGM) is scheduled for Friday, July 31, 2026, at 12:30 PM to seek shareholder approval for the preferential issue.
Governance
Neutral
2026-06-24 18:56
- Board Meeting to be held on July 02, 2026, to consider a proposal for raising funds, including a preferential issue.
- Trading window for dealing in company securities will be closed from June 24, 2026, to July 04, 2026.
Governance
Positive
2026-06-24 18:41
- Board meeting scheduled for Thursday, July 02, 2026, to consider a proposal for raising funds, including a preferential issue.
- Trading window for dealing in company securities will be closed from June 24, 2026, to July 04, 2026.
Financials
Negative
2026-05-29 22:06
Standalone Revenue from Operations for the year ended 31st March 2026 was ₹25.47 Cr vs ₹25.04 Cr (▲1.72% YoY). EBITDA was -₹0.57 Cr vs ₹5.44 Cr (▼110.40% YoY). PAT was ₹3.87 Cr vs ₹3.85 Cr (▲0.32% YoY). EBITDA Margin was -2.22% vs 21.71% (▼2393bps). The company reported audited financial results for the year and half year ended 31st March 2026, with auditors issuing an unmodified opinion.
Financials
Negative
2026-05-29 22:03
Standalone Annual Revenue for the year ended March 31, 2026, was ₹2,546.88 Lakhs compared to ₹2,503.92 Lakhs in the previous year (▲1.72% YoY). EBITDA was -₹66.95 Lakhs against ₹543.58 Lakhs (▼112.31% YoY). Net Profit (PAT) was ₹386.52 Lakhs compared to ₹385.28 Lakhs (▲0.32% YoY). EBITDA Margin contracted significantly from 21.71% to -2.63% (▼2434 bps).
Financials
Negative
2026-05-29 21:51
Revenue ₹2,546.88 Lakhs vs ₹2,503.92 Lakhs (▲1.72% YoY), EBITDA ₹555.02 Lakhs vs ₹600.68 Lakhs (▼7.60% YoY), PAT ₹386.52 Lakhs vs ₹385.28 Lakhs (▲0.32% YoY). EBITDA Margin 21.79% vs 23.99% (▼220bps).
Governance
Neutral
2026-05-21 20:52
ASSTON PHARMACEUTICALS LIMITED announced that a Board Meeting will be held on Friday, 29th May, 2026, at 3:00 P.M. to consider and approve the Audited Financial Statements and Financial Results for the Financial Year and Quarter ended March 31, 2026. The board will also consider the statement of deviation of funds as per SEBI regulations.